Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837
by
,
Jaco A. C. van Bruggen
1,2,3,4,5,†, 
Anne W. J. Martens
1,2,3,4,5,†,
Sanne H. Tonino
1,3,4,5 and
Arnon P. Kater
1,3,4,5,* 1
Department of Hematology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
2
Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
3
Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands
4
Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, The Netherlands
5
Lymphoma and Myeloma Center Amsterdam, LYMMCARE, 1105 AZ Amsterdam, The Netherlands
*
Author to whom correspondence should be addressed.
†
These authors contributed equally.
Cancers 2021, 13(19), 4738; https://doi.org/10.3390/cancers13194738
Submission received: 18 August 2021
/
Accepted: 19 August 2021
/
Published: 22 September 2021
(This article belongs to the Special Issue B Cell Malignancies (including B Cell Lymphoma, Multiple Myeloma and B-CLL))
In the original article [1], reference [46] was not cited correctly in Table 1. The citation has now been inserted in Section 2.1. “Immune Checkpoint Blockade”, Table 1: the original citation “Zinzani et al., 2019” should read “Zinzani et al., 2019 [46]”.
In the original article, reference [84] was not cited correctly in Table 3. The citation has now been inserted in Section 2.3. “Chimeric Antigen Receptor Therapy”, Table 3: the original citation “Fraietta et al., 2016 [78]” should read: “Fraietta et al., 2016 [84]”.
The reference citation numbers from Section 3.2. “T-Cell Skewing”, paragraph two, line three onwards were incorrectly written as a result of four missing references in the reference section. They have been corrected after the references were reinserted with the following numbers: [103], [117], [153] and [192]:
- 103.
- Tinhofer, I.; Weiss, L.; Gassner, F.; Rubenzer, G.; Holler, C.; Greil, R. Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J. Immunother. 2009, 32, 302–309, doi:10.1097/CJI.0b013e318197b5e4.
- 117.
- Song, D.G.; Ye, Q.; Carpenito, C.; Poussin, M.; Wang, L.P.; Ji, C.; Figini, M.; June, C.H.; Coukos, G.; Powell, D.J., Jr. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011, 71, 4617–4627, doi:10.1158/0008-5472.CAN-11-0422.
- 153.
- Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Gorgun, G.; Le Dieu, R.; Blum, W.; Byrd, J.C.; Gribben, J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Investig. 2008, 118, 2427–2437, doi:10.1172/JCI35017.
- 192.
- Ramsay, A.G.; Evans, R.; Kiaii, S.; Svensson, L.; Hogg, N.; Gribben, J.G. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121, 2704–2714, doi:10.1182/blood-2012-08-448332.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.
Reference
- van Bruggen, J.A.C.; Martens, A.W.J.; Tonino, S.H.; Kater, A.P. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
van Bruggen, J.A.C.; Martens, A.W.J.; Tonino, S.H.; Kater, A.P. Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837. Cancers 2021, 13, 4738. https://doi.org/10.3390/cancers13194738
AMA Style
van Bruggen JAC, Martens AWJ, Tonino SH, Kater AP. Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837. Cancers. 2021; 13(19):4738. https://doi.org/10.3390/cancers13194738
Chicago/Turabian Stylevan Bruggen, Jaco A. C., Anne W. J. Martens, Sanne H. Tonino, and Arnon P. Kater. 2021. "Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837" Cancers 13, no. 19: 4738. https://doi.org/10.3390/cancers13194738
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
